Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Taro Pharmaceutical Industries, a multinational, science-based pharmaceutical company, has received final approval from the FDA for its abbreviated new drug application for lamotrigine tablets 25mg, 100mg, 150mg, and 200mg.
Subscribe to our email newsletter
Taro has received tentative approval for this abbreviated new drug application (ANDA) in March 2008.
Lamotrigine is a prescription product used for the treatment of seizures and is bioequivalent to GlaxoSmithKline’s Lamictal tablets.